{"id":"intravitreal-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Endophthalmitis"},{"rate":null,"effect":"Retinal detachment"},{"rate":null,"effect":"Cataract progression"},{"rate":null,"effect":"Intraocular pressure elevation"},{"rate":null,"effect":"Vitreous hemorrhage"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Intravitreal injection bypasses systemic circulation and the blood-retinal barrier, allowing high local concentrations of drugs at the site of disease while minimizing systemic exposure. This delivery method is used for various therapeutic agents including anti-VEGF antibodies, corticosteroids, and other biologics targeting retinal conditions. The specific mechanism depends on the active pharmaceutical ingredient being injected.","oneSentence":"Intravitreal injection is a route of administration that delivers therapeutic agents directly into the vitreous cavity of the eye to treat retinal and posterior segment diseases.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:16:51.077Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Retinal diseases requiring direct intraocular delivery (specific indication not specified in available information)"}]},"trialDetails":[{"nctId":"NCT06890026","phase":"","title":"Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-15","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Treatment-naïve","enrollment":742},{"nctId":"NCT06912633","phase":"PHASE2","title":"Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)","status":"RECRUITING","sponsor":"jCyte, Inc","startDate":"2025-06-20","conditions":"Retinitis Pigmentosa","enrollment":60},{"nctId":"NCT07496567","phase":"PHASE2, PHASE3","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)","status":"NOT_YET_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2026-04-30","conditions":"Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":960},{"nctId":"NCT07007065","phase":"PHASE3","title":"Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-05","conditions":"Neovascular Age-related Macular Degeneration","enrollment":561},{"nctId":"NCT06864988","phase":"PHASE3","title":"4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2025-03-03","conditions":"Macular Neovascularization Secondary to Age-Related Macular Degeneration","enrollment":480},{"nctId":"NCT07348588","phase":"PHASE1, PHASE2","title":"Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centro de Pesquisa Rubens Siqueira","startDate":"2024-03-01","conditions":"Retinitis Pigmentosa (RP), Extensive Macular Atrophy With Pseudodrusen (EMAP)","enrollment":30},{"nctId":"NCT07215234","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-10-09","conditions":"Geographic Atrophy","enrollment":104},{"nctId":"NCT05681884","phase":"PHASE2","title":"Safety and Efficacy of Faricimab in Patients With NPDR","status":"COMPLETED","sponsor":"Greater Houston Retina Research","startDate":"2023-05-16","conditions":"Non-Proliferative Diabetic Retinopathy","enrollment":179},{"nctId":"NCT07484074","phase":"PHASE1","title":"A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324","status":"COMPLETED","sponsor":"Ollin Biosciences, Inc.","startDate":"2025-02-12","conditions":"Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration","enrollment":164},{"nctId":"NCT07425522","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2026-04-01","conditions":"Diabetic Macular Edema","enrollment":93},{"nctId":"NCT07118670","phase":"PHASE4","title":"High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Edward Wood, MD","startDate":"2025-12-08","conditions":"Proliferative Diabetic Retinopathy (PDR)","enrollment":40},{"nctId":"NCT05642325","phase":"PHASE3","title":"Vamikibart in Participants With Uveitic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2023-03-23","conditions":"Uveitic Macular Edema","enrollment":256},{"nctId":"NCT06893965","phase":"NA","title":"Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL","status":"RECRUITING","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2025-07-08","conditions":"Macular Diseases","enrollment":100},{"nctId":"NCT07481500","phase":"NA","title":"Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety","status":"NOT_YET_RECRUITING","sponsor":"Jakkrit Juhong","startDate":"2026-06","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":120},{"nctId":"NCT05536297","phase":"PHASE3","title":"Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2022-09-26","conditions":"Geographic Atrophy, Age-Related Macular Degeneration","enrollment":278},{"nctId":"NCT06176352","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-03-06","conditions":"Choroidal Neovascularization Secondary to Pathologic Myopia","enrollment":280},{"nctId":"NCT06891443","phase":"PHASE3","title":"Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)","status":"RECRUITING","sponsor":"Laboratoires Thea","startDate":"2025-06-04","conditions":"Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis","enrollment":32},{"nctId":"NCT07235085","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy","status":"RECRUITING","sponsor":"Ocular Therapeutix, Inc.","startDate":"2025-11-17","conditions":"Non-Proliferative Diabetic Retinopathy","enrollment":930},{"nctId":"NCT07449936","phase":"PHASE3","title":"COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME","status":"RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2026-02-26","conditions":"Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)","enrollment":240},{"nctId":"NCT05217680","phase":"PHASE3","title":"Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-05-24","conditions":"Diabetic Macular Edema","enrollment":510},{"nctId":"NCT07429474","phase":"PHASE1","title":"Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema","status":"NOT_YET_RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2026-03-01","conditions":"Immunogenicity, Anti-drug Antibodies (ADAs)","enrollment":60},{"nctId":"NCT05811351","phase":"PHASE2","title":"A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-06","conditions":"Geographic Atrophy","enrollment":305},{"nctId":"NCT04853251","phase":"PHASE4","title":"A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2021-12-14","conditions":"Neovascular Age-related Macular Degeneration","enrollment":188},{"nctId":"NCT03364153","phase":"PHASE2","title":"Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-01-12","conditions":"Stargardt's Macular Dystrophy","enrollment":121},{"nctId":"NCT07461441","phase":"PHASE3","title":"Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy","status":"RECRUITING","sponsor":"Yeungnam University College of Medicine","startDate":"2026-03-01","conditions":"Polypoidal Choroidal Vasculopathy (PCV), Age Related Macular Degeneration","enrollment":50},{"nctId":"NCT07053358","phase":"EARLY_PHASE1","title":"Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-07-02","conditions":"Neovascular Age-related Macular Degeneration","enrollment":10},{"nctId":"NCT07362927","phase":"EARLY_PHASE1","title":"Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-03","conditions":"Diabetic Macular Edema (DME)","enrollment":32},{"nctId":"NCT06929143","phase":"","title":"A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2025-04-14","conditions":"Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)","enrollment":3000},{"nctId":"NCT07290244","phase":"PHASE1","title":"Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)","status":"RECRUITING","sponsor":"Life Biosciences Inc.","startDate":"2026-03-02","conditions":"Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)","enrollment":18},{"nctId":"NCT07456826","phase":"PHASE4","title":"Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections","status":"NOT_YET_RECRUITING","sponsor":"Harrow Inc","startDate":"2026-04","conditions":"Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion","enrollment":236},{"nctId":"NCT06961370","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-07-16","conditions":"Geographic Atrophy, Age-related Macular Degeneration","enrollment":132},{"nctId":"NCT04108156","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-09-30","conditions":"Diabetic Macular Edema","enrollment":634},{"nctId":"NCT06196840","phase":"PHASE2","title":"Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innostellar Biotherapeutics Co.,Ltd","startDate":"2024-01-24","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":50},{"nctId":"NCT07449923","phase":"PHASE3","title":"CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME","status":"RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2026-02-09","conditions":"Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)","enrollment":240},{"nctId":"NCT06779773","phase":"","title":"A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-01-22","conditions":"Geographic Atrophy, Macular Degeneration","enrollment":1000},{"nctId":"NCT06668064","phase":"PHASE3","title":"A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2024-10-22","conditions":"Wet Age Related Macular Degeneration, wAMD","enrollment":400},{"nctId":"NCT06683742","phase":"PHASE3","title":"A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2024-11-27","conditions":"Wet Age Related Macular Degeneration, wAMD","enrollment":400},{"nctId":"NCT02652780","phase":"PHASE3","title":"Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)","status":"COMPLETED","sponsor":"GenSight Biologics","startDate":"2016-01","conditions":"Optic, Atrophy, Hereditary, Leber","enrollment":37},{"nctId":"NCT03326336","phase":"PHASE1, PHASE2","title":"Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa","status":"ACTIVE_NOT_RECRUITING","sponsor":"GenSight Biologics","startDate":"2018-09-26","conditions":"Non-syndromic Retinitis Pigmentosa","enrollment":10},{"nctId":"NCT07303296","phase":"PHASE2","title":"Efficacy and Safety Study of Bilateral IVT Injection of GS010 at Two Dose Levels in LHON Patients","status":"RECRUITING","sponsor":"GenSight Biologics","startDate":"2026-01-22","conditions":"Leber Hereditary Optic Disease","enrollment":14},{"nctId":"NCT03672968","phase":"","title":"EAP_GS010_single Patient","status":"NO_LONGER_AVAILABLE","sponsor":"GenSight Biologics","startDate":"","conditions":"Leber Hereditary Optic Neuropathy (Optic, Atrophy, Hereditary, Leber)","enrollment":""},{"nctId":"NCT02652767","phase":"PHASE3","title":"Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation","status":"COMPLETED","sponsor":"GenSight Biologics","startDate":"2016-02-23","conditions":"Optic, Atrophy, Hereditary, Leber","enrollment":39},{"nctId":"NCT03406104","phase":"PHASE3","title":"RESCUE and REVERSE Long-term Follow-up","status":"COMPLETED","sponsor":"GenSight Biologics","startDate":"2018-01-09","conditions":"Leber Hereditary Optic Neuropathy","enrollment":62},{"nctId":"NCT03295071","phase":"","title":"REALITY LHON Registry","status":"COMPLETED","sponsor":"GenSight Biologics","startDate":"2018-01-03","conditions":"Leber Hereditary Optic Neuropathy","enrollment":44},{"nctId":"NCT05224102","phase":"PHASE4","title":"A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2022-02-28","conditions":"Diabetic Macular Edema","enrollment":218},{"nctId":"NCT04519619","phase":"","title":"Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)","status":"RECRUITING","sponsor":"Bayer","startDate":"2020-11-27","conditions":"Neovascular Glaucoma","enrollment":480},{"nctId":"NCT06847542","phase":"PHASE3","title":"A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-11-27","conditions":"Neovascular Age-related Macular Degeneration","enrollment":250},{"nctId":"NCT07438119","phase":"PHASE4","title":"Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients","status":"NOT_YET_RECRUITING","sponsor":"Kun Liu","startDate":"2026-03-15","conditions":"Diabetic Macular Edema (DME)","enrollment":114},{"nctId":"NCT07439887","phase":"PHASE1, PHASE2","title":"Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease","status":"RECRUITING","sponsor":"Ray Therapeutics, Inc.","startDate":"2026-01-28","conditions":"Stargardt Disease","enrollment":18},{"nctId":"NCT07440225","phase":"PHASE2, PHASE3","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)","status":"NOT_YET_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2026-03-31","conditions":"Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":960},{"nctId":"NCT07434713","phase":"","title":"EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-07-14","conditions":"Age-Related Macular Degeneration (AMD)","enrollment":50},{"nctId":"NCT06970665","phase":"PHASE4","title":"A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2025-07-08","conditions":"Geographic Atrophy, Age-Related Macular Degeneration","enrollment":20},{"nctId":"NCT07133438","phase":"PHASE4","title":"Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2025-08-01","conditions":"Retinal Vein Occlusion (RVO)","enrollment":120},{"nctId":"NCT04503551","phase":"PHASE3","title":"A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-10","conditions":"Diabetic Retinopathy","enrollment":174},{"nctId":"NCT07427719","phase":"","title":"Retinopathy of Prematurity - Visual Function and Retinal Structure","status":"NOT_YET_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2026-04-01","conditions":"Retinopathy of Prematurity (ROP), Prematurity Complications, Cerebral Visual Impairment","enrollment":140},{"nctId":"NCT06460844","phase":"PHASE1","title":"Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ray Therapeutics, Inc.","startDate":"2024-08-27","conditions":"Retinitis Pigmentosa, Choroideremia","enrollment":10},{"nctId":"NCT06178055","phase":"PHASE2","title":"A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)","status":"COMPLETED","sponsor":"Kyoto Drug Discovery and Development Co., Ltd.","startDate":"2024-04-16","conditions":"Central Retinal Artery Occlusion","enrollment":17},{"nctId":"NCT07403825","phase":"PHASE4","title":"Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material","status":"NOT_YET_RECRUITING","sponsor":"Biobizkaia Health Research Institute","startDate":"2026-04","conditions":"Macular Degeneration, Age Related","enrollment":100},{"nctId":"NCT05504291","phase":"PHASE2","title":"A Study to Give Treatment Inside the Eye to Treat Retinoblastoma","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2022-11-04","conditions":"Bilateral Retinoblastoma, Childhood Intraocular Retinoblastoma, Group D Retinoblastoma","enrollment":26},{"nctId":"NCT04704921","phase":"PHASE2, PHASE3","title":"Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-12-29","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":630},{"nctId":"NCT07390253","phase":"","title":"Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vienna Institute for Research in Ocular Surgery","startDate":"2024-09-18","conditions":"Neovascular (Wet) Age-Related Macular Degeneration","enrollment":50},{"nctId":"NCT07406854","phase":"PHASE3","title":"A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wuhan Neurophth Biotechnology Limited Company","startDate":"2024-09-19","conditions":"Leber Hereditary Optic Neuropathy (LHON)","enrollment":95},{"nctId":"NCT07160179","phase":"PHASE1, PHASE2","title":"Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-08-13","conditions":"Geographic Atrophy, Age-Related Macular Degeneration","enrollment":66},{"nctId":"NCT05197270","phase":"PHASE1, PHASE2","title":"4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2021-12-09","conditions":"Neovascular (Wet) Age-Related Macular Degeneration","enrollment":215},{"nctId":"NCT06550011","phase":"PHASE1, PHASE2","title":"Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Avirmax Biopharma Inc","startDate":"2024-08-07","conditions":"Neovascular (Wet) AMD","enrollment":18},{"nctId":"NCT07064759","phase":"PHASE3","title":"Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2025-07-22","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":480},{"nctId":"NCT07406438","phase":"PHASE1","title":"To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Kexing Pharmaceutical Co., Ltd.","startDate":"2026-02-12","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":48},{"nctId":"NCT04634578","phase":"PHASE2","title":"Bevacizumab Treatment For Type 1 ROP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jaeb Center for Health Research","startDate":"2022-05-01","conditions":"Retinopathy of Prematurity","enrollment":77},{"nctId":"NCT07402876","phase":"PHASE3","title":"A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma","status":"RECRUITING","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2026-02","conditions":"Primary Vitreoretinal Lymphoma","enrollment":20},{"nctId":"NCT02557451","phase":"NA","title":"Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents and Age Related Macular Degeneration Complications","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2016-04-28","conditions":"Subretinal Haematoma Linked to AMD","enrollment":91},{"nctId":"NCT04432831","phase":"PHASE3","title":"A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-08-05","conditions":"Diabetic Macular Edema","enrollment":1479},{"nctId":"NCT03635268","phase":"","title":"Endophthalmitis After Intravitreal Injection of Antiangiogenic Agents or Corticosteroids, a Cohort Study of the French Population of Patients Who Received Injections Over 9 Years","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2016-01-01","conditions":"Intravitreal Injection","enrollment":360000},{"nctId":"NCT06627179","phase":"PHASE2","title":"Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene","status":"RECRUITING","sponsor":"Laboratoires Thea","startDate":"2024-12-11","conditions":"Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind","enrollment":81},{"nctId":"NCT07389577","phase":"PHASE3","title":"A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)","status":"COMPLETED","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","startDate":"2022-03-01","conditions":"Wet Age-related Macular Degeneration","enrollment":443},{"nctId":"NCT04340505","phase":"","title":"Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2019-08-08","conditions":"Uveitis","enrollment":30},{"nctId":"NCT04567303","phase":"PHASE1, PHASE2","title":"Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-10-28","conditions":"Macular Degeneration","enrollment":177},{"nctId":"NCT04663750","phase":"PHASE3","title":"Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).","status":"RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2021-04-16","conditions":"Eye Diseases, Macular Degeneration, Wet, Sub-Macular Hemorrhage","enrollment":210},{"nctId":"NCT06795048","phase":"PHASE4","title":"A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-03-14","conditions":"Neovascular Age-related Macular Degeneration (nAMD)","enrollment":274},{"nctId":"NCT05844982","phase":"PHASE3","title":"Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy","status":"RECRUITING","sponsor":"Jaeb Center for Health Research","startDate":"2023-11-21","conditions":"Radiation Retinopathy, Visual Impairment","enrollment":600},{"nctId":"NCT07375901","phase":"NA","title":"the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"The Filatov Institute of Eye Diseases and Tissue Therapy","startDate":"2021-03-25","conditions":"AMD","enrollment":30},{"nctId":"NCT04690556","phase":"PHASE3","title":"Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD","status":"COMPLETED","sponsor":"Lupin Ltd.","startDate":"2020-09-14","conditions":"Neovascular Age-related Macular Degeneration","enrollment":600},{"nctId":"NCT05904028","phase":"PHASE3","title":"Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD","status":"RECRUITING","sponsor":"Jaeb Center for Health Research","startDate":"2023-11-09","conditions":"Neovascular Age-related Macular Degeneration","enrollment":600},{"nctId":"NCT07365371","phase":"PHASE4","title":"A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-01-01","conditions":"Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)","enrollment":174},{"nctId":"NCT03845049","phase":"PHASE3","title":"Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2019-07-03","conditions":"Macular Telangiectasia","enrollment":16},{"nctId":"NCT07338097","phase":"NA","title":"Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema","status":"ENROLLING_BY_INVITATION","sponsor":"CMH Multan Institute of Medical Sciences","startDate":"2025-09-07","conditions":"Diabetic Macular Edema (DME)","enrollment":116},{"nctId":"NCT06847854","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2022-12-08","conditions":"Diabetic Macular Edema","enrollment":151},{"nctId":"NCT02556736","phase":"PHASE1, PHASE2","title":"AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-14","conditions":"Advanced Retinitis Pigmentosa","enrollment":14},{"nctId":"NCT07275840","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD","status":"RECRUITING","sponsor":"Innovent Biologics Technology Limited (Shanghai R&D Center)","startDate":"2025-12-05","conditions":"Neovascular Age-related Macular Degeneration","enrollment":800},{"nctId":"NCT05769153","phase":"PHASE1, PHASE2","title":"Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"RECRUITING","sponsor":"Alcon Research","startDate":"2023-12-06","conditions":"Neovascular Age-related Macular Degeneration (nAMD)","enrollment":140},{"nctId":"NCT06422507","phase":"PHASE3","title":"A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-05-29","conditions":"Diabetic Macular Edema","enrollment":333},{"nctId":"NCT07311863","phase":"EARLY_PHASE1","title":"UGX202 Injection in Patients With Advanced Retinitis Pigmentosa","status":"NOT_YET_RECRUITING","sponsor":"Suzhou UgeneX Therapeutics Co., Ltd.","startDate":"2026-01","conditions":"Retinitis Pigmentosa (RP)","enrollment":6},{"nctId":"NCT07301775","phase":"PHASE4","title":"Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery","status":"NOT_YET_RECRUITING","sponsor":"Ahmad Zeeshan Jamil","startDate":"2026-01-01","conditions":"Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Cataract","enrollment":166},{"nctId":"NCT06825702","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema","status":"RECRUITING","sponsor":"Kiora Pharmaceuticals, Inc.","startDate":"2025-05-01","conditions":"Macular Edema","enrollment":28},{"nctId":"NCT05959304","phase":"PHASE4","title":"Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-12-11","conditions":"Diabetic Macular Edema","enrollment":63},{"nctId":"NCT06164587","phase":"PHASE1, PHASE2","title":"Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Michelle Abou-Jaoude","startDate":"2024-04-18","conditions":"Geographic Atrophy, Age-Related Macular Degeneration","enrollment":30},{"nctId":"NCT05520177","phase":"PHASE3","title":"A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss","status":"COMPLETED","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2022-12-27","conditions":"Branch Retinal Vein Occlusion","enrollment":351},{"nctId":"NCT07214740","phase":"PHASE3","title":"Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe","status":"COMPLETED","sponsor":"Apellis Pharmaceuticals, Inc.","startDate":"2025-10-24","conditions":"Geographic Atrophy Secondary to Age-related Macular Degeneration","enrollment":44},{"nctId":"NCT05666804","phase":"PHASE3","title":"Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-02-06","conditions":"Macular Polypoidal Choroidal Vasculopathy (PCV)","enrollment":148},{"nctId":"NCT05643118","phase":"PHASE1","title":"Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Olix Pharmaceuticals, Inc.","startDate":"2023-01-04","conditions":"Neovascular Age-related Macular Degeneration","enrollment":21},{"nctId":"NCT03940690","phase":"PHASE3","title":"Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease","status":"TERMINATED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2019-10-24","conditions":"Retinal Telangiectasis, Coats Disease","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8653,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avastin","BEOVU","Eylea","intravitreal bevacizumab"],"phase":"phase_3","status":"active","brandName":"Intravitreal Injection","genericName":"Intravitreal Injection","companyName":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","companyId":"instituto-universitario-de-oftalmobiolog-a-aplicada-institute-of-applied-ophthal","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intravitreal injection is a route of administration that delivers therapeutic agents directly into the vitreous cavity of the eye to treat retinal and posterior segment diseases. Used for Retinal diseases requiring direct intraocular delivery (specific indication not specified in available information).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}